Navigation Links
Mylan Announces Move to NASDAQ Stock Market
Date:12/12/2008

PITTSBURGH, Dec. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that it will move its stock exchange listing to The NASDAQ Stock Market, an exchange of The NASDAQ OMX Group Inc. (Nasdaq: NDAQ), from The New York Stock Exchange (NYSE) effective Dec. 29. The company will be listed on the NASDAQ Global Select Market, and its common stock will continue to trade under the "MYL" ticker symbol.

Mylan's Vice Chairman and CEO Robert J. Coury commented: "Notwithstanding the obvious financial benefits that NASDAQ offers, the decision to switch Mylan's listing was also driven by the fact that for quite some time a greater portion of our total trading volume was already crossing on NASDAQ trading facilities. This decision, we believe, will further enhance Mylan's overall needs and efficiencies."

Mylan's mandatory convertible preferred stock and 1.25% convertible notes also will move to NASDAQ with the ticker symbols "MYLNP" and "MYLNG," respectively.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
2. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
3. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
4. Mylan Declares Quarterly Preferred Stock Dividend
5. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
6. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
7. Mylan to Offer $400 Million in Cash Convertible Notes
8. Mylan Creates New Womens Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
9. Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... , ... "Success Files," a short- and long-form documentary style ... disease estimated to affect the lives of more than 5 million Americans living ... leading voice in the fight for cure and research into the disease, its ...
(Date:9/22/2017)... ... 2017 , ... Egg freezing and embryo freezing are both ... slight statistical advantage for live births, frozen eggs offer many advantages, depending on ... medical treatment or who are concerned about the decline of their fertility as ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Bill Howe ... to its customers, and give back to the community. For over 37 years, they ... most successful companies serving plumbing in San Diego. They were chosen as ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, ... Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on Lower East ... pieces, such as Zen Kodo mat. Wanderlust , one of the largest US ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
(Date:8/29/2017)... 29, 2017 ivWatch, LLC, the leading provider of continuous ... it has been awarded an Innovative Technology contract from Vizient, Inc., ... ... aid in the early detection of peripheral IV infiltration and extravasation ... The Innovative Technology contract was awarded ...
Breaking Medicine Technology: